Objective: To investigate the effect of extract of Gingko biloba (EGb) on soluble intercellular cell adhesion molecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) in patients with early diabetic nephropathy (DN).
Methods: Sixty-three patients with DN in early stage were randomly assigned to the control group (29 cases) and the treatment group (34 cases). Both groups were treated by routine treatment, and with EGb given to the treatment group additionally. The treatment course was 2 months. Serum sICAM-1 and sVCAM-1 were determined with ELISA before and after treatment, and urinary albumin excretion rate (UAER), fasting plasma glucose (FPG), serum creatinine (SCr) and blood lipids, etc. were examined as well.
Results: The levels of serum sICAM-1 and sVCAM-1 were significantly lower in both groups after treatment than those before treatment (P < 0.05 or P < 0.01), and the decrement in the treatment group was more significant than that in the control group (P < 0.01). And the levels of UAER, SCr and blood lipids decreased in the treatment group after treatment (P < 0.05 or P < 0.01).
Conclusion: EGb could retard the development of early DN through decreasing the levels of serum sICAM-1 and sVCAM-1.